158 related articles for article (PubMed ID: 10462235)
1. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
Rothstein EP; Anderson EL; Decker MD; Poland GA; Reisinger KS; Blatter MM; Jacobson RM; Mink CA; Gennevois D; Izu AE; Sinangil F; Langenberg AG
Vaccine; 1999 Aug; 17(23-24):2999-3006. PubMed ID: 10462235
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
Annunziato PW; Rothstein EP; Bernstein HH; Blatter MM; Reisinger KS; Pichichero ME
Arch Pediatr Adolesc Med; 1994 May; 148(5):503-7. PubMed ID: 8180641
[TBL] [Abstract][Full Text] [Related]
3. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
5. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
[TBL] [Abstract][Full Text] [Related]
7. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
Huang LM; Lee CY; Lin TY; Chen JM; Lee PI; Hsu CY
Vaccine; 1996 Jun; 14(9):916-22. PubMed ID: 8843635
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
[TBL] [Abstract][Full Text] [Related]
9. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
10. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
11. [Humoral response to the injection of acellular Pertussis vaccine].
Zakharova NS; Remova TN; Britsina MV; Shmeleva EI; Mertsalova NU; Zaĭtsev EM; Ozeretskovskaia MN; Bazhanova IG; Ermolova EV
Zh Mikrobiol Epidemiol Immunobiol; 2001; (6):40-4. PubMed ID: 11881494
[TBL] [Abstract][Full Text] [Related]
12. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange.
Buasri W; Impoolsup A; Boonchird C; Luengchaichawange A; Prompiboon P; Petre J; Panbangred W
BMC Microbiol; 2012 Apr; 12():61. PubMed ID: 22524455
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
Podda A; Nencioni L; Marsili I; Peppoloni S; Volpini G; Donati D; Di Tommaso A; De Magistris MT; Rappuoli R
Vaccine; 1991 Oct; 9(10):741-5. PubMed ID: 1759492
[TBL] [Abstract][Full Text] [Related]
14. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers.
Littmann M; Hülsse C; Riffelmann M; Wirsing von König CH
Vaccine; 2008 May; 26(19):2344-9. PubMed ID: 18396360
[TBL] [Abstract][Full Text] [Related]
15. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
Prelog M; Almanzar G; Rieber N; Ottensmeier B; Zlamy M; Liese J
Vaccine; 2013 Jan; 31(2):387-93. PubMed ID: 23142306
[TBL] [Abstract][Full Text] [Related]
16. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
[TBL] [Abstract][Full Text] [Related]
18. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
[TBL] [Abstract][Full Text] [Related]
19. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484
[TBL] [Abstract][Full Text] [Related]
20. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
Wood N; Marshall H; White OJ; Holt PG; McIntyre P
Pediatr Infect Dis J; 2014 May; 33(5):511-7. PubMed ID: 24445839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
